Alkem Laboratories Reports Q1 Unaudited Results for FY26; Profit Stands at 5,209.8 Million
Alkem Laboratories Limited announced the approval of its Standalone and Consolidated Unaudited Financial Results for the quarter ending June 30, 2026. The results were approved by the Board of Directors during a meeting held on August 14, 2026. These quarterly figures reflect the company's performance across both consolidated entities and standalone operations.The company’s Consolidated Financial Results for the quarter ending June 30, 2026, showed Total Income at 38,929.0 million. The results reported a profit for the period of 5,209.8 million and a total comprehensive income of 5,238.6 million.
The key financial highlights for consolidated operations across recent periods are detailed in the table below:
| Particulars | Q ended 30.06.2026 (Unaudited) | Q ended 31.03.2026 (Unaudited) | Q ended 30.06.2025 (Unaudited) | Q ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Total Income | 38,929.0 million | 38,033.9 million | 35,076.3 million | 152,956.2 million |
| Total Expenses | 31,209.1 million | 32,455.7 million | 27,495.5 million | 122,499.0 million |
| Profit for the period | 5,209.8 million | 2,511.1 million | 6,679.1 million | 23,511.6 million |
In the standalone segment, Alkem Laboratories reported Total Income of 28,043.5 million for the quarter ending June 30, 2026. The company achieved a profit for the period of 7,984.2 million and total comprehensive income matching this figure.
The performance trend of standalone operations is summarized below:
| Particulars | Q ended 30.06.2026 (Unaudited) | Q ended 31.03.2026 (Unaudited) | Q ended 30.06.2025 (Unaudited) | Q ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Total Income | 28,043.5 million | 24,641.3 million | 24,887.5 million | 102,190.8 million |
| Total Expenses | 20,059.3 million | 20,088.3 million | 18,233.7 million | 75,533.7 million |
| Profit for the period | 7,984.2 million | 2,170.6 million | 6,561.6 million | 25,226.2 million |
The financial results incorporated several exceptional items and operational assessments. In the quarter ending March 31, 2026, the Company recognized a provision for impairment amounting to 747 million following a review of investments in real estate. Additionally, management assessed the impact of revised regulatory frameworks related to labor codes, recognizing an estimated liability towards gratuity and leave encashment at 602.7 million for the quarter ended March 31, 2026, and 1,130.6 million for the year ending March 31, 2026. A gain of 142.9 million resulting from the sale of its Indore manufacturing facility in the quarter ended June 30, 2025 was also disclosed as an exceptional item.
The results were reviewed by Deloitte Haskins & Sells LLP, whose report concluded that nothing has come to their attention that suggests the accompanying statements, prepared according to Indian Accounting Standard 34 "Interim Financial Reporting," contain any material misstatement or fail to disclose required information.
ALKEM Stock Price Movement
Alkem Laboratories Limited shares today slipped by 1.64% to settle at ₹5360, having shed ₹89.50 during the trading session. The stock saw robust activity in post-market hours, with a total traded volume amounting to 564,384 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: